55274-44-7 Usage
Uses
Used in Organic Synthesis:
2-Nitrophenyl2,3,4-tri-O-acetyl-b-D-glucuronidemethylester is used as an intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows it to be a valuable building block in the synthesis of complex organic molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Nitrophenyl2,3,4-tri-O-acetyl-b-D-glucuronidemethylester is used as a key component in the development of new drugs. Its versatile chemical structure enables it to be modified and functionalized to create novel drug candidates with potential therapeutic applications.
Used in Research and Development:
2-Nitrophenyl2,3,4-tri-O-acetyl-b-D-glucuronidemethylester is also utilized in research and development laboratories for studying various chemical reactions and mechanisms. Its unique properties make it an ideal candidate for exploring new reaction pathways and understanding the behavior of different functional groups in organic chemistry.
Used in Analytical Chemistry:
In analytical chemistry, 2-Nitrophenyl2,3,4-tri-O-acetyl-b-D-glucuronidemethylester can be employed as a reference compound or a standard for the development and validation of analytical methods. Its distinct chemical structure and properties make it suitable for calibrating instruments and ensuring the accuracy of analytical results.
Check Digit Verification of cas no
The CAS Registry Mumber 55274-44-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,2,7 and 4 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 55274-44:
(7*5)+(6*5)+(5*2)+(4*7)+(3*4)+(2*4)+(1*4)=127
127 % 10 = 7
So 55274-44-7 is a valid CAS Registry Number.
55274-44-7Relevant academic research and scientific papers
GLUCURONIDE PRODRUGS OF TOFACITINIB
-
, (2018/09/28)
The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I): (Formula (I)) where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
-
, (2018/12/11)
The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
